Newamsterdam Pharma Stock Performance
| NAMS Stock | 17.88 0.35 2.00% |
The company secures a Beta (Market Risk) of -0.9, which conveys possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning NewAmsterdam Pharma are expected to decrease slowly. On the other hand, during market turmoil, NewAmsterdam Pharma is expected to outperform it slightly. At this point, NewAmsterdam Pharma has a negative expected return of -0.0266%. Please make sure to verify NewAmsterdam Pharma's value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if NewAmsterdam Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days NewAmsterdam Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable primary indicators, NewAmsterdam Pharma is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Actual Historical Performance (%)
One Day Return 2 | Five Day Return (6.92) | Year To Date Return (31.12) | Ten Year Return 68.49 | All Time Return 68.49 |
Last Split Factor 1:1 | Last Split Date 2022-11-23 |
1 | Cinctive Capital Management LP Boosts Stock Position in NewAmsterdam Pharma | 12/04/2024 |
2 | Disposition of 4894 shares by Forgrowth Nap B.v. of NewAmsterdam Pharma at 27.109 subject to Rule 16b-3 | 12/11/2024 |
3 | NewAmsterdam Pharma Announces Pricing of Upsized 416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants | 12/12/2024 |
4 | Disposition of 56506 shares by Forgrowth Nap B.v. of NewAmsterdam Pharma at 25.4452 subject to Rule 16b-3 | 12/19/2024 |
5 | Disposition of 5629 shares by Forgrowth Nap B.v. of NewAmsterdam Pharma at 26.1274 subject to Rule 16b-3 | 12/20/2024 |
6 | Disposition of 25132 shares by Forgrowth Nap B.v. of NewAmsterdam Pharma at 25.4904 subject to Rule 16b-3 | 12/23/2024 |
7 | Disposition of 16164 shares by Forgrowth Nap B.v. of NewAmsterdam Pharma at 25.66 subject to Rule 16b-3 | 12/24/2024 |
8 | Disposition of 33438 shares by Forgrowth Nap B.v. of NewAmsterdam Pharma at 26.0072 subject to Rule 16b-3 | 12/26/2024 |
9 | Disposition of 41472 shares by Forgrowth Nap B.v. of NewAmsterdam Pharma at 25.9522 subject to Rule 16b-3 | 12/27/2024 |
10 | Acquisition by Kastelein Johannes Jacob Pieter of 200000 shares of NewAmsterdam Pharma at 25.96 subject to Rule 16b-3 | 01/02/2025 |
11 | Acquisition by Davidson Michael H. of 670467 shares of NewAmsterdam Pharma at 25.85 subject to Rule 16b-3 | 01/06/2025 |
12 | Acquisition by Mayur Somaiya of 38000 shares of NewAmsterdam Pharma subject to Rule 16b-3 | 01/07/2025 |
13 | Acquisition by Smither John W of 6960 shares of NewAmsterdam Pharma subject to Rule 16b-3 | 01/08/2025 |
14 | NewAmsterdam Pharma Company N.V. Analysts Recommend This 52-Week High Stocks Now | 01/15/2025 |
15 | Acquisition by Van Der Kamp Hilde Johanna of 6960 shares of NewAmsterdam Pharma subject to Rule 16b-3 | 01/21/2025 |
16 | Deep Dive Into NewAmsterdam Pharma Stock Analyst Perspectives - Benzinga | 01/24/2025 |
17 | Disposition of 23815 shares by Douglas Kling of NewAmsterdam Pharma at 23.46 subject to Rule 16b-3 | 01/27/2025 |
18 | Disposition of 5148 shares by Douglas Kling of NewAmsterdam Pharma at 21.93 subject to Rule 16b-3 | 01/28/2025 |
19 | NewAmsterdam Pharma to Present at Guggenheims SMID Cap Biotech Conference | 01/29/2025 |
20 | NewAmsterdam Pharma Shares Gap Down Should You Sell | 01/30/2025 |
21 | Disposition of 13578 shares by Douglas Kling of NewAmsterdam Pharma subject to Rule 16b-3 | 01/31/2025 |
22 | NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 02/07/2025 |
23 | Both private equity firms who control a good portion of NewAmsterdam Pharma Company N.V. along with institutions must be dismayed after last weeks 8.1 percent d... | 02/14/2025 |
24 | Disposition of 90782 shares by Douglas Kling of NewAmsterdam Pharma at 19.54 subject to Rule 16b-3 | 02/18/2025 |
25 | Disposition of 9218 shares by Douglas Kling of NewAmsterdam Pharma at 19.23 subject to Rule 16b-3 | 02/19/2025 |
26 | NewAmsterdam Pharma Co NV Announces Participation in Key Investor Conferences | 02/25/2025 |
| Begin Period Cash Flow | 467.7 M |
NewAmsterdam |
NewAmsterdam Pharma Relative Risk vs. Return Landscape
If you would invest 1,985 in NewAmsterdam Pharma on November 28, 2024 and sell it today you would lose (197.00) from holding NewAmsterdam Pharma or give up 9.92% of portfolio value over 90 days. NewAmsterdam Pharma is currently does not generate positive expected returns and assumes 6.1238% risk (volatility on return distribution) over the 90 days horizon. In different words, 54% of stocks are less volatile than NewAmsterdam, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
NewAmsterdam Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NewAmsterdam Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NewAmsterdam Pharma, and traders can use it to determine the average amount a NewAmsterdam Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0043
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NAMS |
Estimated Market Risk
| 6.12 actual daily | 54 54% of assets are less volatile |
Expected Return
| -0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average NewAmsterdam Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NewAmsterdam Pharma by adding NewAmsterdam Pharma to a well-diversified portfolio.
NewAmsterdam Pharma Fundamentals Growth
NewAmsterdam Stock prices reflect investors' perceptions of the future prospects and financial health of NewAmsterdam Pharma, and NewAmsterdam Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NewAmsterdam Stock performance.
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (0.86) % | ||||
| Current Valuation | 1.46 B | ||||
| Shares Outstanding | 92.39 M | ||||
| Price To Book | 4.96 X | ||||
| Price To Sales | 56.98 X | ||||
| Revenue | 12.76 M | ||||
| EBITDA | (176.86 M) | ||||
| Net Income | (176.94 M) | ||||
| Total Debt | 60 K | ||||
| Book Value Per Share | 4.11 X | ||||
| Cash Flow From Operations | (141.22 M) | ||||
| Earnings Per Share | (2.21) X | ||||
| Market Capitalization | 2.29 B | ||||
| Total Asset | 347.1 M | ||||
| Retained Earnings | (316.97 M) | ||||
| Working Capital | 296.89 M | ||||
About NewAmsterdam Pharma Performance
Assessing NewAmsterdam Pharma's fundamental ratios provides investors with valuable insights into NewAmsterdam Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the NewAmsterdam Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.46) | (0.48) | |
| Return On Capital Employed | (0.64) | (0.61) | |
| Return On Assets | (0.46) | (0.48) | |
| Return On Equity | (0.71) | (0.67) |
Things to note about NewAmsterdam Pharma performance evaluation
Checking the ongoing alerts about NewAmsterdam Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NewAmsterdam Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NewAmsterdam Pharma generated a negative expected return over the last 90 days | |
| NewAmsterdam Pharma has high historical volatility and very poor performance | |
| NewAmsterdam Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 12.76 M. Net Loss for the year was (176.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NewAmsterdam Pharma generates negative cash flow from operations | |
| NewAmsterdam Pharma has a frail financial position based on the latest SEC disclosures | |
| Over 84.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: NewAmsterdam Pharma Co NV Announces Participation in Key Investor Conferences |
- Analyzing NewAmsterdam Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NewAmsterdam Pharma's stock is overvalued or undervalued compared to its peers.
- Examining NewAmsterdam Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NewAmsterdam Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NewAmsterdam Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NewAmsterdam Pharma's stock. These opinions can provide insight into NewAmsterdam Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.